ReviewPerspectives in clinical research
Drug repurposing: Clinical practices and regulatory pathways.
Review in Perspectives in clinical research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of AI-assisted drug repurposing in neurological disorders: a systematic review of validation strategies, challenges and opportunities.Journal of nanobiotechnology · 2026Pooled it
- Targeting the NLRP3-NEK7 axis with rebamipide: Drug repurposing in Parkinson's disease.Neural regeneration research · 2026Article
- Marbofloxacin Suppresses Breast Cancer Growth Through Oxidative Stress and Metabolic Reprogramming with Predicted HSP90AA1-EGFR Network Modulation.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Rupatadine Ameliorates Cisplatin-Induced Hepatotoxicity in Rats: Targeting HMGB1/TLR4/NF-κB and NLRP3/Caspase-1 Signaling Pathways.Journal of biochemical and molecular toxicology · 2026Article
- Integrating single-cell and bulk transcriptomic perturbation resources reveals complementary therapeutic spaces for drug repurposing.bioRxiv : the preprint server for biology · 2026Article
- Medicinal Chemistry Perspectives on Drug Repurposing: Innovative Approaches and Therapeutic Breakthrough.Therapeutic innovation & regulatory science · 2026Review
- Combining Mendelian Randomization and Experimental Validation to Reveal the Causal Relationship Between Hallux Valgus and Serum Metabolites and to Identify Their Therapeutic Targets and Relevant Components.Food science & nutrition · 2026Article
- Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions.AAPS PharmSciTech · 2026Review
- Personalized Combination Therapy in Bladder Cancer: cAMP Modulators Synergize with 5-FU and Modulate Redox Programs.Cancers · 2026Article
- Review
- Recent advances in drug repositioning and rediscovery for different therapeutic activities utilizing updated technological approaches.Molecular diversity · 2026Review
- Drug Repurposing for Metabolic-Associated Fatty Liver Disease: Current Evidence, Challenges, and Future Perspectives.Drug design, development and therapy · 2026Review
- Antifibrotic Efficacy of Daclatasvir Against Pulmonary Fibrosis: Insights From Network Pharmacology, Molecular Docking, Dynamics, and Preclinical Evaluations.Chemistry & biodiversity · 2026Article
- molIEreVIS: exploring and interpreting the evidence behind drug repurposing predictions.Frontiers in bioinformatics · 2026Article
- The evolving landscape of cancer cachexia prevention: A review of metronomic chemotherapy and drug repurposing strategies.Medical oncology (Northwood, London, England) · 2025Review
- Luliconazole-Loaded Nanoliposomes as a Repurposing Strategy to Combat Memory Dysfunction in LPS-Induced Alzheimer's Rats.ACS omega · 2025Article
- Reinvestigating Pyrrol-2-One-Based Compounds: From Antimicrobial Agents to Promising Antitumor Candidates.Pharmaceuticals (Basel, Switzerland) · 2025Article
- BOGO: A Proteome-Wide Gene Overexpression Platform for Discovering Rational Cancer Combination Therapies.bioRxiv : the preprint server for biology · 2025Article
- Antibacterial and antibiofilm efficacy of TMC647055 against methicillin-resistant Staphylococcus aureus.Archives of microbiology · 2025Article
- Silodosin as a Novel Inhibitor of Acetylcholinesterase, Butyrylcholinesterase, and BETA-Secretase 1: In Vitro and In Silico Studies.ACS omega · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug repurposing, also known as drug repositioning or reprofiling, involves identifying new therapeutic uses for existing drugs beyond their original indications. Historical examples include sildenafil citrate transitioning to an erectile dysfunction treatment and thalidomide shifting from a sedative to an immunomodulatory agent. Advocates tout its potential to address unmet medical needs by expediting development, reducing costs, and using drugs with established safety profiles. However, concerns exist regarding specificity for new indications, safety, and regulatory exploitation. Ethical considerations include equitable access, informed consent when using drugs off-label, and transparency. Recent advancements include artificial intelligence (AI) applications, network pharmacology, and omics technologies. Clinical trials explore repurposed drugs' efficacy, with regulatory agencies facilitating approval. Challenges include intellectual property protection, drug target specificity, trial design complexities, and funding limitations. Ethical challenges encompass patient autonomy, potential conflicts of interest due to financial incentives for industries, and resource allocation. Future directions involve precision medicine, AI, and global collaboration. In conclusion, drug repurposing offers a promising pathway for therapeutic innovation but requires careful consideration of its complexities and ethical implications to maximize benefits and minimize risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.